These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

794 related articles for article (PubMed ID: 21154355)

  • 21. Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort.
    Bock P; Fatti G; Grimwood A
    Int Health; 2013 Jun; 5(2):132-8. PubMed ID: 24030113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nevirapine versus efavirenz based antiretroviral treatment in naive Indian patients: comparison of effectiveness in clinical cohort.
    Patel AK; Pujari S; Patel K; Patel J; Shah N; Patel B; Gupte N
    J Assoc Physicians India; 2006 Dec; 54():915-8. PubMed ID: 17334006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Choice of initial antiretroviral drugs and treatment outcomes among HIV-infected patients in sub-Saharan Africa: systematic review and meta-analysis of observational studies.
    Ayele TA; Worku A; Kebede Y; Alemu K; Kasim A; Shkedy Z
    Syst Rev; 2017 Aug; 6(1):173. PubMed ID: 28841912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.
    Jordan WC; Jefferson R; Yemofio F; Tolbert L; Conlon V; Carroll H; Green DC; Green A; Green R
    J Natl Med Assoc; 2003 Dec; 95(12):1152-7. PubMed ID: 14717471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical uses of non-nucleoside reverse transcriptase inhibitors.
    Harris M; Montaner JS
    Rev Med Virol; 2000; 10(4):217-29. PubMed ID: 10891870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and durability of nevirapine in antiretroviral drug näive patients.
    Lange JM
    J Acquir Immune Defic Syndr; 2003 Sep; 34 Suppl 1():S40-52. PubMed ID: 14562857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz.
    van Leth F; Conway B; Laplumé H; Martin D; Fisher M; Jelaska A; Wit FW; Lange JM;
    Antivir Ther; 2004 Oct; 9(5):721-8. PubMed ID: 15535409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis.
    Pillay P; Ford N; Shubber Z; Ferrand RA
    PLoS One; 2013; 8(7):e68995. PubMed ID: 23894391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
    van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJ; Schechter M; Murphy RL; Horban A; Hall DB; Lange JM; Reiss P
    PLoS Med; 2004 Oct; 1(1):e19. PubMed ID: 15526045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis.
    Shubber Z; Calmy A; Andrieux-Meyer I; Vitoria M; Renaud-Théry F; Shaffer N; Hargreaves S; Mills EJ; Ford N
    AIDS; 2013 Jun; 27(9):1403-12. PubMed ID: 23343913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymphocyte mitochondrial depolarization and apoptosis in HIV-1-infected HAART patients.
    Karamchand L; Dawood H; Chuturgoon AA
    J Acquir Immune Defic Syndr; 2008 Aug; 48(4):381-8. PubMed ID: 18614930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
    Shey MS; Kongnyuy EJ; Alobwede SM; Wiysonge CS
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD005481. PubMed ID: 23543540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals.
    Núñez M; Soriano V; Martín-Carbonero L; Barrios A; Barreiro P; Blanco F; García-Benayas T; González-Lahoz J
    HIV Clin Trials; 2002; 3(3):186-94. PubMed ID: 12032877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.
    Wu PY; Cheng CY; Liu CE; Lee YC; Yang CJ; Tsai MS; Cheng SH; Lin SP; Lin DY; Wang NC; Lee YC; Sun HY; Tang HJ; Hung CC
    PLoS One; 2017; 12(2):e0171596. PubMed ID: 28222098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful viral suppression with subsequent efavirenz-based regimen in HIV-1-infected patients who stop nevirapine prior to discontinuation of the NRTI backbone.
    Chimsuntorn S; Sungkanuparph S; Manosuthi W
    J Int Assoc Physicians AIDS Care (Chic); 2010; 9(1):43-5. PubMed ID: 20071597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
    Swaminathan S; Padmapriyadarsini C; Venkatesan P; Narendran G; Ramesh Kumar S; Iliayas S; Menon PA; Selvaraju S; Pooranagangadevi NP; Bhavani PK; Ponnuraja C; Dilip M; Ramachandran R
    Clin Infect Dis; 2011 Oct; 53(7):716-24. PubMed ID: 21890776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.
    Chang LW; Harris J; Humphreys E
    Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
    Domingo P; Ribera E
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
    Manosuthi W; Mankatitham W; Lueangniyomkul A; Chimsuntorn S; Sungkanuparph S
    HIV Med; 2008 May; 9(5):294-9. PubMed ID: 18400076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
    Teeranaipong P; Sirivichayakul S; Mekprasan S; Ohata PJ; Avihingsanon A; Ruxrungtham K; Putcharoen O
    PLoS One; 2016; 11(4):e0154221. PubMed ID: 27120449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.